Today: 12 July 2026

Khadija Saeed

Khadija Saeed is a financial markets reporter at TS2.tech, specializing in stocks, technology and emerging industries. She studied economics and finance at the London School of Economics and previously worked in market research before moving into financial journalism. Her coverage focuses on the companies, innovations and economic trends influencing global investors.

Booking Holdings Inc. (BKNG) Stock: What to Know Before the US Market Opens on Dec. 15, 2025

Booking Holdings Inc. (BKNG) Stock: What to Know Before the US Market Opens on Dec. 15, 2025

Booking Holdings Inc. heads into the Dec. 15 US session with investors balancing three big themes: resilient travel demand, a clear push to widen margins through its Transformation Program, and a fast-evolving competitive landscape shaped by AI-driven travel discovery—particularly Google’s expansion of AI Mode into trip planning and, eventually, bookings. Q4 Capital+1
14 December 2025
··
Circle Internet Group (CRCL) Stock: What to Know Before the U.S. Market Opens on Dec. 15, 2025

Circle Internet Group (CRCL) Stock: What to Know Before the U.S. Market Opens on Dec. 15, 2025

Circle Internet Group, Inc. heads into Monday’s U.S. session with investors weighing a major regulatory milestone against a sharply lower stock price. Shares closed Friday at $83.47, finishing a volatile week of trading as Wall Street digested Circle’s conditional approval from the Office of the Comptroller of the Currency to establish a national trust bank tied to the company’s USDC stablecoin infrastructure. Circle Investor Relations+1
14 December 2025
·
1 … 760 761 762 763 764 … 880

Stock Market Today

  • Ascendis Pharma (ASND) rallies 24%; valuation premium clouds outlook
    July 12, 2026, 2:35 AM EDT. Ascendis Pharma (ASND) has surged 24% for the month as investors pile in. Still, shares trade at a P/E of 29.7x, not as high as some rivals, but more than the biotech sector's 17.4x average-so there's a valuation premium. The value score is 3 out of 6, leaving it unclear if the stock is cheap or expensive. Market focus is still on whether Ascendis can turn its pipeline into steady revenues. Delays in cash flow or the need for more capital could hit the stock. After a flat year, investors are trying to judge if shares now reflect the company's growth outlook in this sector.
Go toTop